Teva Pharmaceutical Industries Ltd. TEVA today announced that
the U.S. Food and Drug Administration (FDA) has approved Quartette™
(levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the
prevention of pregnancy. Quartette™ represents the next generation of
extended regimen oral contraceptives to be approved by the FDA, and was
designed to minimize breakthrough bleeding (BTB) between scheduled
periods. The approval of Quartette™ demonstrates Teva's continued
commitment to the development and production of an innovative range of
pharmaceutical products that support the health of women around the
world.
“Breakthrough bleeding can be experienced with any birth control pill,
especially during the first few months, and is one of the reasons a
large
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in